$CYDY CytoDyn final mTNBC report indicates as much as 980% increase in 12-month overall survival and up to 660% in 12-month modified progression free survival.
$CYDY CytoDyn announced preliminary results from 30 mTNBC patients treated with leronlimab. decreases in CAMLs after 4 doses of leronlimab were identified in over 70% of patients and were associated with a 450% significant increase in overall survival at 12-month analysis.
$CYDY CytoDyn partner Biomm S.A. plans to submit authorization to conduct Phase 3 clinical studies of leronlimab with ANVISA in Brazil in the next few days.
$CYDY CytoDyn to submit newly completed topline report of CD12 trial results to regulatory agencies in multiple countries including India and Philippines.
$CYDY CytoDyn's leronlimab decreased mortality at 14 days by 82% with statistically significant p-value of 0.0233 amongst critically ill COVID-19 patients.
